|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication December 22, 2005.
Revised April 9, 2006.
Accepted for publication April 14, 2006.
The bulky side chains of antiestrogens hinder folding of
the ligand-binding domain (LBD) of estrogen receptors
(ERs) into a transcriptionally active conformation. The
presence of a tertiary amine in the side chain of
raloxifene, which interacts with a negatively charged
residue in helix H3 of the ER LBD (D351 in hER
),
is important for antiestrogenicity in animal and
cellular models. Here we have examined the influence of
tertiary amine substituents and of mutations at position
351 in hER
on the activity profiles of tamoxifen
derivatives. Results obtained in several cellular model
systems suggest that the degree of antagonist activity
of tamoxifen derivatives does not strictly correlate
with the basicity of the side chain, but depends on an
optimal spatial relationship between the tertiary amine
of these antiestrogens and the negative charge at
position 351. While displacement of the negative charge
at position 351 (mutation D351E) had little effect on
transcriptional activity in the presence of tamoxifen,
it drastically increased the partial agonist activity of
a tamoxifen derivative with improved antagonist activity
as well as that of raloxifene. Our results suggest that
contrary to raloxifene, tamoxifen and most of its
derivatives do not interact with D351 in an optimal
manner, although this can be improved by modifying
tertiary amine substituents
Key words:
Sex hormones, Structure-activity relationships and modeling, Transcription targets
This article has been cited by other articles:
![]() |
V. Bourdeau, J. Deschenes, D. Laperriere, M. Aid, J. H. White, and S. Mader Mechanisms of primary and secondary estrogen target gene regulation in breast cancer cells Nucleic Acids Res., January 17, 2008; 36(1): 76 - 93. [Abstract] [Full Text] [PDF] |
||||